Triple-negative breast cancers (TNBCs) are a heterogenous group of breast cancers characterized by poor prognosis because they are not amenable to targeted therapies. We have taken into account that altered expression of Raf-1 kinase inhibitor protein (RKIP), a tumor and metastasis suppressor and a promoter of drug-induced apoptosis, is frequent in TNBCs and may be involved in their aggressive biology. Interestingly, the analysis of the possible mechanisms of RKIP downregulation in TNBCs permits the identification and recapitulation of different possible approaches, including epigenetic modulation, e.g., by DNA demethylating agents or histone deacetylase inhibition, and NF-κB inhibition. These approaches are currently of great interest in the field of TNBC therapy.

D'Alessandro, N., Poma, P., Labbozzetta, M., Vivona, N., & NOTARBARTOLO DI VILLAROSA, M. (2014). Mechanisms of Raf-1 Kinase Inhibitor Protein Dysregulation in Triple-Negative Breast Cancers and Identification of Possible Novel Therapeutic Approaches for These Tumors. FORUM ON IMMUNOPATHOLOGICAL DISEASES AND THERAPEUTICS, 5(3-4), 215-222 [10.1615/ForumImmunDisTher.2015013936].

Mechanisms of Raf-1 Kinase Inhibitor Protein Dysregulation in Triple-Negative Breast Cancers and Identification of Possible Novel Therapeutic Approaches for These Tumors

D'ALESSANDRO, Natale;POMA, Paola;LABBOZZETTA, Manuela;VIVONA, Nicoletta;NOTARBARTOLO DI VILLAROSA, Monica
2014

Abstract

Triple-negative breast cancers (TNBCs) are a heterogenous group of breast cancers characterized by poor prognosis because they are not amenable to targeted therapies. We have taken into account that altered expression of Raf-1 kinase inhibitor protein (RKIP), a tumor and metastasis suppressor and a promoter of drug-induced apoptosis, is frequent in TNBCs and may be involved in their aggressive biology. Interestingly, the analysis of the possible mechanisms of RKIP downregulation in TNBCs permits the identification and recapitulation of different possible approaches, including epigenetic modulation, e.g., by DNA demethylating agents or histone deacetylase inhibition, and NF-κB inhibition. These approaches are currently of great interest in the field of TNBC therapy.
Settore BIO/14 - Farmacologia
Settore MED/06 - Oncologia Medica
D'Alessandro, N., Poma, P., Labbozzetta, M., Vivona, N., & NOTARBARTOLO DI VILLAROSA, M. (2014). Mechanisms of Raf-1 Kinase Inhibitor Protein Dysregulation in Triple-Negative Breast Cancers and Identification of Possible Novel Therapeutic Approaches for These Tumors. FORUM ON IMMUNOPATHOLOGICAL DISEASES AND THERAPEUTICS, 5(3-4), 215-222 [10.1615/ForumImmunDisTher.2015013936].
File in questo prodotto:
File Dimensione Formato  
FIDT13936_final.pdf

non disponibili

Descrizione: articolo principale
Dimensione 612.58 kB
Formato Adobe PDF
612.58 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/10447/147425
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 1
  • ???jsp.display-item.citation.isi??? ND
social impact